VistaGen Therapeutics Inc (NASDAQ: VTGN) stock closed at $3.08 on 11/8/23 after a major decline of -11.4%. Relative to the market the stock has been weak over the last nine months and has declined -3.1% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to fall short of the cost of capital, VTGN is expected to be a modest Value Eraser.
VistaGen Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. VistaGen Therapeutics has a neutral Power Rating of 44 but a poor Appreciation Score of 16, with the Lowest Value Trend Rating the result.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment